abstract |
The present invention relates to the application of gluconate, saccharate or lactate of GLN-1062 in the preparation of medicines for the treatment of brain diseases associated with cognitive impairment in mammals, the medicines are administered through the mucosa, wherein the The mucosal administration is selected from intranasal administration, sublingual administration or buccal administration. Due to the mode of administration and chemical nature of the compounds of the invention, the selected route of administration has optimal brain delivery. |